SCTL · Societal Cdmo, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $94.64M | $90.21M | $75.36M | $66.50M | $99.22M | $69.34M |
| Cost of Revenue | $76.50M | $67.08M | $55.54M | $54.13M | $50.98M | $43.16M |
| Gross Profit | $18.14M | $23.14M | $19.82M | $12.37M | $48.24M | $26.18M |
| R&D | - | - | - | - | - | $39.98M |
| SG&A | $21.02M | $21.95M | $18.37M | $18.12M | $14.32M | $36.88M |
| Total Operating Expenses | $98.21M | $89.94M | $74.95M | $74.84M | $75.59M | $131.39M |
| D&A | $8.22M | $7.41M | $6.53M | $5.96M | $5.82M | $7.85M |
| Operating Income | ($3.57M) | $279.0K | $412.0K | ($8.34M) | $23.63M | ($54.04M) |
| Interest Expense | $9.96M | $14.06M | $15.13M | $19.16M | $19.81M | $8.76M |
| Income Tax | $132.0K | $1.10M | $0 | - | $0 | $17.44M |
| Net Income | ($13.27M) | ($19.88M) | ($11.37M) | ($27.50M) | ($18.63M) | ($79.72M) |
| EPS - Basic | ($0.14) | $0.34 | ($0.26) | ($1.16) | ($3.90) | - |
| EPS - Diluted | ($0.14) | $0.34 | ($0.26) | ($1.16) | ($3.90) | - |
Balance Sheet
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.10M | $14.99M | $25.22M | $23.76M | $19.15M | $38.51M |
| Accounts Receivable | $16.58M | $15.95M | $11.91M | $9.03M | $14.39M | $12.87M |
| Inventory | $10.26M | $10.30M | $8.92M | $11.61M | $15.07M | $10.70M |
| Accounts Payable | $1.31M | $1.47M | $2.08M | $1.80M | $989.0K | $4.51M |
| Current Assets | $53.46M | $55.59M | $57.53M | $54.07M | $60.16M | $71.14M |
| Total Assets | $153.47M | $157.44M | $160.32M | $103.42M | $110.46M | $155.49M |
| Current Liabilities | $49.99M | $22.81M | $17.73M | $7.80M | $6.49M | $29.03M |
| Long-term Debt | $339.0K | $30.97M | $92.13M | $108.10M | $110.32M | $64.24M |
| Total Liabilities | $94.81M | $97.58M | $118.25M | $117.52M | $117.17M | $174.99M |
| Stockholders' Equity | $58.66M | $59.86M | $42.06M | ($14.10M) | ($6.71M) | ($19.50M) |
| Retained Earnings | ($278.91M) | ($265.63M) | ($245.75M) | $2.82M | ($206.88M) | ($188.25M) |
Cash Flow
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $10.86M | ($3.64M) | $10.86M | $9.24M | $11.02M | ($3.20M) |
| Investing Cash Flow | ($8.24M) | ($8.35M) | ($7.60M) | ($7.60M) | ($3.67M) | ($3.77M) |
| Financing Cash Flow | $2.34M | $1.77M | $4.15M | $4.15M | $27.73M | $51.68M |
| CapEx | $8.24M | $8.35M | $5.29M | $7.60M | $8.34M | $10.53M |
| Free Cash Flow | $2.62M | ($11.99M) | $5.57M | $1.64M | $2.68M | ($13.73M) |
Ratios
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 19.2% | 25.6% | 26.3% | 18.6% | 48.6% | 37.8% |
| Operating margin | -3.8% | 0.3% | 0.5% | -12.5% | 23.8% | -77.9% |
| EBITDA margin | 4.9% | 8.5% | 9.2% | -3.6% | 29.7% | -66.6% |
| Net margin | -14.0% | -22.0% | -15.1% | -41.4% | -18.8% | -115.0% |
| Free cash flow margin | 2.8% | -13.3% | 7.4% | 2.5% | 2.7% | -19.8% |
| FCF / Net income | -0.20 | 0.60 | -0.49 | -0.06 | -0.14 | 0.17 |
| R&D / Revenue | - | - | - | - | - | 57.7% |
| SG&A / Revenue | 22.2% | 24.3% | 24.4% | 27.3% | 14.4% | 53.2% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -8.6% | -12.6% | -7.1% | -26.6% | -16.9% | -51.3% |
| Return on equity | -22.6% | -33.2% | -27.0% | 195.0% | 277.6% | 408.8% |
| Return on invested capital | -4.8% | 0.2% | 0.2% | - | 18.0% | -95.4% |
| Liquidity | ||||||
| Current ratio | 1.07 | 2.44 | 3.24 | 6.93 | 9.28 | 2.45 |
| Quick ratio | 0.86 | 1.99 | 2.74 | 5.44 | 6.95 | 2.08 |
| Cash ratio | 0.16 | 0.66 | 1.42 | 3.04 | 2.95 | 1.33 |
| Leverage | ||||||
| Debt / Equity | 0.01 | 0.52 | 2.19 | -7.67 | -16.44 | -3.29 |
| Debt / Assets | 0.00 | 0.20 | 0.57 | 1.05 | 1.00 | 0.41 |
| Debt / EBITDA | 0.07 | 4.03 | 13.27 | - | 3.75 | - |
| Interest coverage | -0.4x | 0.0x | 0.0x | -0.4x | 1.2x | -6.2x |
| Equity multiplier | 2.62 | 2.63 | 3.81 | -7.33 | -16.46 | -7.97 |
| Liabilities / Assets | 0.62 | 0.62 | 0.74 | 1.14 | 1.06 | 1.13 |
| Efficiency | ||||||
| Asset turnover | 0.62 | 0.57 | 0.47 | 0.64 | 0.90 | 0.45 |
| Inventory turnover | 7.45 | 6.51 | 6.23 | 4.66 | 3.38 | 4.03 |
| Days sales outstanding | 64d | 65d | 58d | 50d | 53d | 68d |
| Days inventory outstanding | 49d | 56d | 59d | 78d | 108d | 90d |
| Days payable outstanding | 6d | 8d | 14d | 12d | 7d | 38d |
| Cash conversion cycle | 107d | 113d | 103d | 116d | 154d | 120d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 4.9% | 19.7% | 13.3% | -33.0% | 43.1% | -3.5% |
| Revenue CAGR (3y) | 12.5% | -3.1% | 2.8% | -2.5% | 12.7% | 10.1% |
| Revenue CAGR (5y) | 6.4% | 4.7% | 1.7% | 5.1% | - | - |
| Gross profit growth (YoY) | -21.6% | 16.7% | 60.3% | -74.4% | 84.3% | -22.2% |
| Operating income growth (YoY) | - | -32.3% | - | - | - | -34.1% |
| Net income growth (YoY) | 33.2% | -74.9% | 58.7% | -47.6% | 76.6% | -59.2% |
| EPS growth (YoY) | - | - | 77.6% | 70.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 240.4% | -39.0% | - | 40.9% |
| FCF CAGR (5y) | - | - | - | -23.0% | - | - |
| Book value growth (YoY) | -2.0% | 42.3% | - | -110.1% | 65.6% | - |
Stability scores
Altman Z′
FY 2023 · bankruptcy risk
-0.72
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2023 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Societal CDMO against the 5 most active filers in the same SIC group.